Next Article in Journal
Antibody Responses to SARS-CoV-2 Antigens in Humans and Animals
Next Article in Special Issue
Influenza Vaccination and Non-Pharmaceutical Measure Effectiveness for Preventing Influenza Outbreaks in Schools: A Surveillance-Based Evaluation in Beijing
Previous Article in Journal
Specific Antibodies and Arachidonic Acid Mediate the Protection Induced by the Schistosoma mansoni Cysteine Peptidase-Based Vaccine in Mice
Previous Article in Special Issue
Impact of Pre-Existing Immunity on Live Attenuated Influenza Vaccine-Induced Cross-Protective Immunity
Commentary

Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity

1
Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
2
The School of Chemistry and Molecular Biosciences, The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Queensland 4072, Australia
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 683; https://doi.org/10.3390/vaccines8040683
Received: 23 October 2020 / Revised: 10 November 2020 / Accepted: 11 November 2020 / Published: 16 November 2020
During the previous influenza seasons, between 2010 and 2016, the live attenuated influenza vaccine (LAIV) provided variable efficacy against influenza in the U.S., causing the recommendation against the use of the LAIV. In striking contrast, pre-clinical studies have repeatedly demonstrated superior efficacy of LAIV against mismatched influenza viruses, compared to inactivated influenza vaccines (IIV). This disparity in reported vaccine efficacies between pre-clinical and clinical studies may in part be explained by limitations of the animal models of influenza. In particular, the absence of pre-existing immunity in animal models has recently emerged as a potential explanation for the discrepancies between preclinical findings and human studies. This commentary focuses on the potential impact of pre-existing immunity on LAIV induced immunogenicity with an emphasis on cross-protective immunity. View Full-Text
Keywords: live attenuated influenza vaccine; pre-existing immunity; pre-existing antibodies; T cell immunogenicity; mucosal responses live attenuated influenza vaccine; pre-existing immunity; pre-existing antibodies; T cell immunogenicity; mucosal responses
MDPI and ACS Style

Roy, S.; Williams, C.M.; Wijesundara, D.K.; Furuya, Y. Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity. Vaccines 2020, 8, 683. https://doi.org/10.3390/vaccines8040683

AMA Style

Roy S, Williams CM, Wijesundara DK, Furuya Y. Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity. Vaccines. 2020; 8(4):683. https://doi.org/10.3390/vaccines8040683

Chicago/Turabian Style

Roy, Sreeja, Clare M. Williams, Danushka K. Wijesundara, and Yoichi Furuya. 2020. "Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity" Vaccines 8, no. 4: 683. https://doi.org/10.3390/vaccines8040683

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop